News

ProKidney: What's Happening With PROK Stock?
The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.
ProKidney’s stock rockets on ‘intriguing’ news, but analyst doesn’t recommend buying
ProKidney’s stock was the biggest gainer and most actively traded on Tuesday following “very intriguing” news regarding the ...
ProKidney Is Soaring on Trial Results. How Should You Play Penny Stock PROK Here?
ProKidney shares soar on promising Rilparencel mid-stage data for chronic kidney disease. But PROK stock remains a high-risk ...
Rilparencel De-Risks Phase 3 As ProKidney Enters Price Discovery
ProKidney Corp. (PROK) shares just saw a massive green day. Results from Phase 2 were compelling and the data sharply ...
ProKidney (PROK) Shares Skyrocket On Promising Kidney Disease Drug Trial Results
ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday ...
ProKidney: Study 'Win' Send Shares Soaring >500% - New Valuation Feels Fair
ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...
Fierce Biotech2d
ProKidney’s CKD cell therapy scores win in one half of phase 2 trial, falls short on other
At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...
InvestorsHub on MSN1d
ProKidney Shares Soar After Citi Lifts Price Target to $9
Shares of ProKidney Corp. (NASDAQ:PROK) jumped 65% in pre-market trading Wednesday, extending the dramatic rally seen on ...
InvestorsHub on MSN2d
ProKidney Shares Double on Strong Phase 2 Data for Kidney Disease Therapy
ProKidney Corp. (NASDAQ:PROK) saw its stock skyrocket 115% following the release of positive topline results from its Phase 2 ...
ProKidney Stock Shoots Up Over 8% After Hours After Staggering 515% Rally On Wednesday
ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours ...
ProKidney Shares Rise on Positive Topline Data in Rilparencel Trial
ProKidney shares jumped 56% in premarket trading after reporting positive topline results from a select population group in a Phase 2 trial evaluating rilparencel in patients with chronic kidney ...